echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [Medicine heaven and earth] 4 + 7 centralized mining breaks out "the power of flood and famine": the price of medicine drops as fast as "lightning", famous pharmaceutical enterprises lose weight, and a large number of pharmaceutical agents change business

    [Medicine heaven and earth] 4 + 7 centralized mining breaks out "the power of flood and famine": the price of medicine drops as fast as "lightning", famous pharmaceutical enterprises lose weight, and a large number of pharmaceutical agents change business

    • Last Update: 2019-03-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    4 + 7 centralized mining work has been carried out in various places First, guiding policies have been issued, and then specific implementation time has been specified According to statistics, 10 cities will implement procurement in March The details are as follows: Xi'an: March 24 is the trial operation stage of Xi'an's volume procurement From March 25, the results of centralized procurement of drugs organized by the State shall be fully implemented, and the payment standard of medical insurance shall be implemented simultaneously Shanghai: it will be implemented on March 20 Exclusive distribution is required After the three parties sign the contract, a special account shall be set up in three times, and payment shall be made according to the progress of 50%, 45% and 5% The medical institution shall pay off the payment of the current month before the 15th day of each month The purchase volume of the unselected varieties shall not exceed that of the unselected varieties, and the gradient price reduction shall be implemented, and the proportion of self payment shall be increased by 10% - 20% Liaoning (Shenyang, Dalian): implemented on March 20, with a settlement period of no more than 30 days After the three parties signed the contract, they set up a special account for three times, which is paid according to the progress of 50%, 45% and 5% The selected price is taken as the payment standard of medical insurance In principle, the same payment standard is applied to the original research drugs, reference preparations and varieties passing the consistency evaluation under the same general name Chongqing: implemented on March 1, requiring medical institutions in the city to report the purchase volume on February 22 Tianjin: implemented on March 1, medical insurance agencies prepaid medical insurance funds to medical institutions twice, and the purchase and sale agreement was signed within six months Beijing: implemented in the middle and late March, the manufacturer is required to arrive before March 15 and select a good distributor (currently in progress) Medical insurance shall be paid in advance at 30% of the purchase amount; the unselected varieties shall refer to Shanghai Guangzhou: the implementation time is unknown Among the third batch of negotiation varieties of Guangzhou GPO medical insurance group, 23 varieties of 4 + 7 centralized mining and unsuccessful manufacturers are involved, which need to be negotiated (man-machine dialogue) Shenzhen: Shenzhen requires that the results of 4 + 7 centralized purchase be embedded in the Shenzhen GPO project, with price linkage, and also include the selected drugs with the terminal retail price being implemented (the specific time hasn't been announced yet) Xiamen: implemented on March 1, and spread that Fujian plans to take 60% of the market share to follow up the 4 + 7 centralized mining, and implemented on April 1 The influence of 4 + 7 centralized mining on the whole industry is far-reaching, whether it is the 11 cities participating in centralized mining or the whole country The three major trends of drug price reduction, drug enterprise slimming and drug agency transfer have emerged In combination with the policies of 4 + 7 centralized purchase in various regions, the situation of drug price reduction will be discussed On the one hand, the price of 4 + 7 winning products is close to the floor price It is inevitable that the centralized purchase price will be fully implemented in 11 cities What about outside 11 cities? As far as Beijing is concerned, it is the main axis of price linkage between Beijing, Tianjin and Hebei At the same time, Beijing price is also a necessary area for drug centralized bidding in Shaanxi, Shandong and other places Once the 4 + 7 price collection is implemented in Beijing, the price radiation to other provinces is also a probability event As for Guangzhou, previously (February 26) Guangzhou drug centralized purchase platform issued notice on matters related to negotiation of the third batch of medical insurance group, which covers 4 + 7 winning products, namely the results of Guangzhou's implementation of 4 + 7 centralized purchase Although the drug bidding method adopted by the province where the city is located is GPO within the province, it is different from 4 + 7 bidding method However, from the perspective of previous bidding history events, industry insiders believe that the price formed by Guangzhou GPO (including market entry price and transaction price) will spread rapidly in Guangdong province through quarterly bidding and GPO events in other cities That is, 4 + 7 centralized purchase price will be adopted by other regions in Guangdong There are also areas within 11 cities, such as Xiamen, Shenyang and Dalian, whose implementation of 4 + 7 price will affect the purchasing situation of the whole province Fujian Province generally follows the bidding mode of small-scale "left-right linkage" + "up-down linkage" in the province, so the price adjustment of the whole province may be started from Xiamen price this time; Liaoning issued a document to encourage other cities to participate in the pilot project with the city as the unit on the premise of meeting the purchase usage, medical insurance payment policy and drug payment settlement On the other hand, some areas outside the city of 11 support the attitude of 4 + 7 bid winning products In the past, online transmission to Anhui organized experts to carry out price negotiation for 4 + 7 related varieties Industry insiders speculated that Anhui would not completely copy the 4 + 7 model, but would carry out a new round of provincial pilot price reduction based on full reference to the 4 + 7 variety reduction (including the unsuccessful price reduction), the variety transaction rate and the final purchase price, combined with its own market reality In December last year, Gansu medicine and medical consumables centralized procurement network issued the notice on the online transaction of dexmedetomidine hydrochloride injection of Yangzijiang Pharmaceutical Group Co., Ltd in the bid winning result of "4 + 7 urban medicine centralized procurement" The province expressed its active response to the national call, fully communicated with relevant enterprises and encouraged enterprises to implement the new bid winning result in Gansu Province In addition, Shanxi requires that the products that are not listed on the Internet in Shandong Province should be listed on the Internet according to the selected price in the national "4 + 7 urban drug centralized procurement" selection results; Shaanxi issues a notice to clarify that the non selected products that are listed in the directory of price Limited network are preferred if the enterprises voluntarily list on the Internet at the 4 + 7 negotiation price in the province In the areas within 4 + 7 centralized mining, the attitude towards the products selected in Africa is "no minimum, only lower" As for Shanghai, the purchase volume of non selected varieties shall not exceed that of selected varieties, and the gradient price reduction shall be implemented, and the self payment proportion shall be increased by 10% - 20% At the same time, Beijing requires that the non selected varieties refer to Shanghai Guangzhou stipulated that the gradient price reduction results of expired patent drugs and other "4 + 7" drugs that were not selected as the highest price drugs were confirmed in Guangzhou Xi'an and Liaoning require that the price of the selected products should not be higher than the price of the selected products before purchasing In Shenzhen, the price after the gradient price reduction in Shanghai is taken as the upper limit of the price of this variety, that is, the same variety will realize the re price reduction after the gradient price reduction in Shanghai Tianjin stipulates that local medical institutions can purchase non selected products, but in principle, the quantity shall not exceed the use amount of selected varieties after conversion according to the proportion relationship Outside of the 11 cities, there was a fierce price war over the products selected from Africa In order to compete for the market beyond 4 + 7, a large number of enterprises are willing to break the floor price, such as Qilu, Hengrui, Zhengda Tianqing, etc On February 28, Liaoning provincial centralized purchase network of drugs and medical consumables issued a notice to approve olanzapine tablets (specification: 5mg * 14 tablets and 10mg * 14 tablets) of the enterprise, which were directly linked to the network at the prices of 77.43 yuan / box and 131.63 yuan / box respectively (the price of each tablet is about 9.4 yuan); and Jiangsu Haosen olanning (7 tablets / box) selected in the same product specification 4 + 7, with the price of 67.51 yuan, on average, 9.64 yuan / tablet Qilu pharmaceutical also took the initiative to reduce the price of pemetrexed disodium for injection Its adjusted price in Liaoning is far lower than Sichuan Huiyu's bid price of 4 + 7 Qilu's jifeitini tablets (0.25g * 10 tablets) have been adjusted to 498 yuan / box underground in Shandong, Zhejiang, Jilin, Heilongjiang, Shaanxi, etc., while AstraZeneca's bid price for the same product is 547 yuan / box, 49 yuan higher than Qilu pharmaceutical On February 21, Yangzijiang Pharmaceutical Group Co., Ltd took the initiative to apply for lowering the purchase price of its over evaluated product dexmedetomidine hydrochloride injection (specification: 1ml: 0.1mg) In the middle of January, Zhengda Tianqing adjusted the net price limit of imatinib mesylate capsule from 872.19 yuan to 586.39 yuan The price cut is 33% This price is 6% lower than the winning price of 623.82 yuan of Haosen 4 + 7 belt purchase At the same time, another owner of imatinib mesylate tablets, the stone drug Ouyi, was not indifferent Later, imatinib mesylate tablets (specification: 100mg * 60 Tablets) were applied for the shortlist of "limited price drugs on the Internet" In late January, 0.1g * 60 capsules of Zhengda Tianqing imatinib mesylate were valued at 586.39 yuan / box, and 0.25g of jifeitini tablets of Qilu pharmaceutical was valued at 498 yuan / box, which was the lowest price in China The lowest price was declared and adjusted in Beijing At the end of December, Hengrui took the initiative to raise the price of dexmedetomidine hydrochloride injection in Anhui Province to 123 yuan Famous pharmaceutical companies should reduce the drug price, promote medical reform, cut off the sales chain with gold, which is to bring a blow to this industry of sink and drain Now, it seems that both the above policies to encourage drug companies to reduce prices and the "perseverance" of enterprises to break through the floor price have achieved initial results Next, we will talk about the impact of 4 + 7 centralized mining on enterprises and drug agents At the beginning of March, Huasen pharmaceutical announced that the following adjustments were made to the company's organizational structure, including the pharmaceutical research institute and sales department On February 28, Jiangsu Enhua pharmaceutical disclosed in its 2018 annual report summary that in 2018, the company had completed the strategic adjustment of increasing R & D investment, promoting the consistency evaluation of key products, and continuously promoting the marketing system reform On the same day, Hengrui pharmaceutical held an online performance presentation meeting Zhou Song, financial director of Hengrui pharmaceutical, said that according to the changes in the internal and external environment, the sales expenses of Hengrui pharmaceutical may decrease steadily, and the R & D expenses will keep a reasonable fluctuation according to the progress and investment of projects in different years While a large number of drug agency transfer banks are making strategic adjustment in drug enterprises, the impact is the livelihood of drug agency According to the previous report of cypress blue, in 2018, the turnover rate of pharmaceutical representatives increased significantly, 70% of the pharmaceutical agents are ready to transform, and 20% of the pharmaceutical agents are already in the process of transformation It is not hard to foresee that the pharmaceutical generation profession that originally relied on the "traditional sales" mode will eventually collapse in the context of volume purchase Information sources: yaozhi.com, Yaozhi elite club, cypress blue, e-medicine manager, pharmaceutical cloud studio, health and knowledge Bureau, etc Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.